Structure and function of prodrug-activating peptidases

被引:3
|
作者
Velilla, Jose A. [1 ]
Kenney, Grace E. [2 ]
Gaudet, Rachelle [1 ]
机构
[1] Harvard Univ, Dept Mol & Cellular Biol, 52 Oxford St, Cambridge, MA 02138 USA
[2] Harvard Univ, Dept Chem & Chem Biol, 38 Oxford St, Cambridge, MA USA
基金
美国国家卫生研究院;
关键词
Prodrug resistance mechanism; Bacterial toxin; Non-ribosomal peptide synthesis; Beta-lactamase; Membrane-embedded peptidase; Sequence similarity network; BIOSYNTHESIS GENE-CLUSTER; SELF-RESISTANCE; ESCHERICHIA-COLI; BETA-LACTAMASES; MECHANISM; ZWITTERMICIN; XENORHABDUS; PAENILAMICIN; AMICOUMACIN; MODEL;
D O I
10.1016/j.biochi.2022.07.019
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Bacteria protect themselves from the toxicity of antimicrobial metabolites they produce through several strategies. In one resistance mechanism, bacteria assemble a non-toxic precursor on an N-acyl-D- asparagine prodrug motif in the cytoplasm, then export it to the periplasm where a dedicated D-amino peptidase hydrolyzes the prodrug motif. These prodrug-activating peptidases contain an N-terminal periplasmic S12 hydrolase domain and C-terminal transmembrane domains (TMDs) of varying lengths: type I peptidases contain three transmembrane helices, and type II peptidases have an additional C-terminal ABC half-transporter. We review studies which have addressed the role of the TMD in function, the substrate specificity, and the biological assembly of ClbP, the type I peptidase that activates colibactin. We use modeling and sequence analyses to extend those insights to other prodrug-activating peptidases and ClbP-like proteins which are not part of prodrug resistance gene clusters. These ClbP-like proteins may play roles in the biosynthesis or degradation of other natural products, including antibiotics, may adopt different TMD folds, and have different substrate specificity compared to prodrug-activating ho-mologs. Finally, we review the data supporting the long-standing hypothesis that ClbP interacts with transporters in the cell and that this association is important for the export of other natural products. Future investigations of this hypothesis as well as of the structure and function of type II peptidases will provide a complete account of the role of prodrug-activating peptidases in the activation and secretion of bacterial toxins.(c) 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:124 / 135
页数:12
相关论文
共 50 条
  • [1] Prodrug-activating systems in suicide gene therapy
    Springer, CJ
    Niculescu-Duvaz, I
    JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (09): : 1161 - 1167
  • [2] Nitroreductase: A prodrug-activating enzyme for cancer gene therapy
    Searle, PF
    Chen, MJ
    Hu, LQ
    Race, PR
    Lovering, AL
    Grove, JI
    Guise, C
    Jaberipour, M
    James, ND
    Mautner, V
    Young, LS
    Kerr, DJ
    Mountain, A
    White, SA
    Hyde, EI
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2004, 31 (11) : 811 - 816
  • [3] Specificity of a Prodrug-Activating Enzyme hVACVase: The Leaving Group Effect
    Sun, Jing
    Dahan, Arik
    Walls, Zachary F.
    Lai, Longsheng
    Lee, Kyung-Dall
    Amidon, Gordon L.
    MOLECULAR PHARMACEUTICS, 2010, 7 (06) : 2362 - 2368
  • [4] Tumor-targeting prodrug-activating bacteria for cancer therapy
    Cheng, C-M
    Lu, Y-L
    Chuang, K-H
    Hung, W-C
    Shiea, J.
    Su, Y-C
    Kao, C-H
    Chen, B-M
    Roffler, S.
    Cheng, T-L
    CANCER GENE THERAPY, 2008, 15 (06) : 393 - 401
  • [5] A nanoengineered tandem nitroreductase: designing a robust prodrug-activating nanoreactor
    Zmyslia, Mariia
    Capper, Michael J.
    Grimmeisen, Michael
    Sartory, Kerstin
    Deuringer, Benedikt
    Abdelsalam, Mohamed
    Shen, Kaiwei
    Jung, Manfred
    Sippl, Wolfgang
    Koch, Hans-Georg
    Kaul, Laurine
    Suess, Regine
    Koehnke, Jesko
    Jessen-Trefzer, Claudia
    RSC CHEMICAL BIOLOGY, 2025, 6 (01): : 21 - 35
  • [6] Tumor-targeting prodrug-activating bacteria for cancer therapy
    C-M Cheng
    Y-L Lu
    K-H Chuang
    W-C Hung
    J Shiea
    Y-C Su
    C-H Kao
    B-M Chen
    S Roffler
    T-L Cheng
    Cancer Gene Therapy, 2008, 15 : 393 - 401
  • [7] Targeted antitumor therapy mediated by prodrug-activating mesenchymal stromal cells
    Kucerova, Lucia
    Durinikova, Erika
    Toro, Lenka
    Cihova, Marina
    Miklikova, Svetlana
    Poturnajova, Martina
    Kozovska, Zuzana
    Matuskova, Miroslava
    CANCER LETTERS, 2017, 408 : 1 - 9
  • [8] Crystal structure of FMN-dependent nitroreductase from Escherichia coli B:: A prodrug-activating enzyme
    Parkinson, GN
    Skelly, JV
    Neidle, S
    JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (20) : 3624 - 3631
  • [9] Delayed Progression of Lung Metastases Following Delivery of a Prodrug-activating Enzyme
    Dore-Savard, Louis
    Chen, Zhihang
    Winnard, Paul T., Jr.
    Krishnamachary, Balaji
    Raman, Venu
    Black, Margaret E.
    Bhujwalla, Zaver M.
    ANTICANCER RESEARCH, 2017, 37 (05) : 2195 - 2200
  • [10] Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies
    Dickopf, Steffen
    Buldun, Can
    Vasic, Vedran
    Georges, Guy
    Hage, Carina
    Mayer, Klaus
    Forster, Matthias
    Wessels, Uwe
    Stubenrauch, Kay-Gunnar
    Benz, Jorg
    Ehler, Andreas
    Lauer, Matthias E.
    Ringler, Philippe
    Kobold, Sebastian
    Endres, Stefan
    Klein, Christian
    Brinkmann, Ulrich
    BIOLOGICAL CHEMISTRY, 2022, 403 (5-6) : 495 - 508